CRC patient tissue microarrays (TMAs) were further employed to explore the correlative relationships between the expression of DYRK2 and patient clinicopathological characteristics using an immunohistochemical (IHC) staining approach, revealing that 65.06% (54/83) of the samples in this TMA specimens in TMA exhibited low levels of DYRK2 expression, whereas low-level DYRK2 expression was only evident in 34.94% (29/83) of the adjacent paracancerous tissue samples (Fig. 1C,D). Here, DYRK2 is linked to colorectal carcinoma.